Bioengineering coagulation factors for improved hemophilia treatments : Comment on: the mutation F309S increases FVIII secretion in human cell line
AUTOR(ES)
Hounkpe, Bidossessi Wilfried, Paula, Erich Vinicius de
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2016-09
RESUMO
Documentos Relacionados
- The F309S mutation increases factor VIII secretion in human cell line
- THE COAGULATION DEFECT IN HEMOPHILIA. STUDIES ON THE REFRACTORY PHASE FOLLOWING REPEATED INJECTIONS OF GLOBULIN SUBSTANCE DERIVED FROM NORMAL HUMAN PLASMA IN HEMOPHILIA 1
- Comment on: Bacteremia in pediatric patients with hematopoietic stem transplantation
- Comment on: "Oral health-related quality of life in children and teens with sickle cell disease"
- Comment on: Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation